Weekly Analysts’ Ratings Updates for Guardant Health (GH)

Several brokerages have updated their recommendations and price targets on shares of Guardant Health (NASDAQ: GH) in the last few weeks:

• 5/28/2026 – Guardant Health was downgraded by Guggenheim from “buy” to “buy”.
• 5/27/2026 – Guardant Health was given a new $160.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 5/26/2026 – Guardant Health had its price target raised by BTIG Research from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Guardant Health was given a new $127.00 price target by Piper Sandler.
• 5/21/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 5/12/2026 – Guardant Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $135.00 price target on the stock.
• 5/8/2026 – Guardant Health had its price target raised by Barclays PLC from $115.00 to $120.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Guardant Health had its price target raised by JPMorgan Chase & Co. from $130.00 to $135.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Guardant Health had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/14/2026 – Guardant Health had its price target lowered by Barclays PLC from $130.00 to $115.00. They now have an “overweight” rating on the stock.

Insider Activity

In other Guardant Health news, insider John G. Saia sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the completion of the sale, the insider directly owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. The trade was a 30.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares of the company’s stock, valued at $7,124,234.78. This represents a 28.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 321,244 shares of company stock worth $34,775,166. Corporate insiders own 5.60% of the company’s stock.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.